tradingkey.logo

Elutia Inc

ELUT
0.987USD
+0.045+4.73%
Close 02/06, 16:00ETQuotes delayed by 15 min
42.00MMarket Cap
LossP/E TTM

Elutia Inc

0.987
+0.045+4.73%

More Details of Elutia Inc Company

Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.

Elutia Inc Info

Ticker SymbolELUT
Company nameElutia Inc
IPO dateOct 08, 2020
CEOMills (C. Randal)
Number of employees51
Security typeOrdinary Share
Fiscal year-endOct 08
Address12510 Prosperity Drive
CitySILVER SPRING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20904
Phone12402471143
Websitehttps://elutia.com/
Ticker SymbolELUT
IPO dateOct 08, 2020
CEOMills (C. Randal)

Company Executives of Elutia Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
447.11K
+78039.00%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
196.12K
+70000.00%
Mr. Guido J. Neels
Mr. Guido J. Neels
Director
Director
118.75K
+50000.00%
Dr. Michelle LeRoux Williams, Ph.D.
Dr. Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
101.93K
+8549.00%
Mr. David Colpman
Mr. David Colpman
Independent Director
Independent Director
31.10K
+12500.00%
Ms. Brigid A. Makes
Ms. Brigid A. Makes
Independent Director
Independent Director
27.00K
+25000.00%
Dr. C. Randal (Randal) Mills, Ph.D.
Dr. C. Randal (Randal) Mills, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew B. (Matt) Ferguson
Mr. Matthew B. (Matt) Ferguson
Chief Financial Officer
Chief Financial Officer
447.11K
+78039.00%
Mr. Kevin L. Rakin
Mr. Kevin L. Rakin
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
196.12K
+70000.00%
Mr. Guido J. Neels
Mr. Guido J. Neels
Director
Director
118.75K
+50000.00%
Dr. Michelle LeRoux Williams, Ph.D.
Dr. Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
101.93K
+8549.00%
Mr. David Colpman
Mr. David Colpman
Independent Director
Independent Director
31.10K
+12500.00%
Ms. Brigid A. Makes
Ms. Brigid A. Makes
Independent Director
Independent Director
27.00K
+25000.00%

Revenue Breakdown

FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Women's health
2.38M
0.00%
Cardiovascular
945.00K
0.00%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Women's health
2.38M
0.00%
Cardiovascular
945.00K
0.00%

Shareholding Stats

Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Highcape Partners, L.P.
12.34%
Nantahala Capital Management, LLC
7.89%
SilverArc Capital Management, LLC
7.07%
Alyeska Investment Group, L.P.
6.55%
AIGH Capital Management, LLC.
4.77%
Other
61.38%
Shareholders
Shareholders
Proportion
Highcape Partners, L.P.
12.34%
Nantahala Capital Management, LLC
7.89%
SilverArc Capital Management, LLC
7.07%
Alyeska Investment Group, L.P.
6.55%
AIGH Capital Management, LLC.
4.77%
Other
61.38%
Shareholder Types
Shareholders
Proportion
Hedge Fund
25.34%
Private Equity
17.11%
Investment Advisor
9.68%
Investment Advisor/Hedge Fund
3.74%
Individual Investor
3.22%
Research Firm
0.31%
Other
40.59%

Institutional Shareholding

Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
54
27.56M
66.51%
--
2025Q3
56
27.56M
70.55%
+656.18K
2025Q2
56
26.90M
72.35%
+168.09K
2025Q1
57
26.74M
61.68%
+4.19M
2024Q4
57
22.31M
69.12%
+1.01M
2024Q3
51
21.30M
59.47%
+5.32M
2024Q2
47
15.98M
79.08%
+3.28M
2024Q1
44
12.69M
88.87%
-5.05M
2023Q4
42
13.41M
85.74%
-1.13M
2023Q3
44
14.54M
55.43%
+5.88M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Highcape Partners, L.P.
4.98M
12.34%
-4.54M
-47.70%
Dec 11, 2025
Nantahala Capital Management, LLC
3.18M
7.89%
--
--
Sep 30, 2025
SilverArc Capital Management, LLC
2.85M
7.07%
+89.30K
+3.23%
Sep 30, 2025
Alyeska Investment Group, L.P.
2.64M
6.55%
--
--
Sep 30, 2025
AIGH Capital Management, LLC.
2.02M
5.01%
-211.28K
-9.46%
Sep 30, 2025
Deerfield Management Company, L.P.
1.37M
3.4%
+1.37M
--
Sep 30, 2025
The Vanguard Group, Inc.
1.18M
2.93%
--
--
Sep 30, 2025
Worth Venture Partners, LLC
1.14M
2.83%
-74.62K
-6.13%
Sep 30, 2025
Knollwood Investment Advisory, LLC
1.03M
2.56%
-3.05K
-0.29%
Sep 30, 2025
Perkins Capital Management, Inc.
1.13M
2.8%
-22.48K
-1.95%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI